KarMac presents at 2026 ASGCT Annual Meeting

May 15, 2026

News

The team attended the 2026 ASGCT Annual Meeting in Boston, MA, to present our latest research on targeting tumor-associated macrophages with CAR-monocytes as a first-in-class approach for cellular therapy in breast cancer.

The full abstract (ASGCT317) will be published in the coming months.

A first-in-class CAR-Monocyte immuno-oncology platform.

About Pipeline Founders News & Publications

Advisors Contact us

KarMac is a first-in-class CAR-Monocyte platform. We engineer immune cells to break down the biological shields around solid tumors, unlocking the immune system's full power to fight back.

KarMac presents at 2026 ASGCT Annual Meeting

More from the archive

Dr. Jennifer Guerriero named a Cancer Research Institute (CRI) Lloyd J. Old STAR

KarMac secures 2026 MGB GCTI Chemistry, Manufacturing & Controls (CMC) Award

KarMac awarded Poster of Distinction at 2026 MGB Celebration of Science

KarMac takes 1st Place Poster Award at 2025 MGB GCTI Symposium

A first-in-class CAR-Monocyte immuno-oncology platform.